Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Stone, Katie ^a   Woods, Emily ^a   Szmania, Susann M ^a   Stephens, Owen W ^a   Garg, Tarun K ^a   Barlogie, Bart ^a   Shaughnessy, John D ^b   Hall, Brett ^c   Reddy, Manjula ^c   Hoering, Antje ^d   Hansen, Emily ^d   van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b GAL Manufacturing Company   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AFRICAN AMERICAN; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; HISPANIC; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84872787678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054610     Document Type: Article

References (27)

1. Castleman B, Towne VW, (1954) Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 251: 396-400.
2. Castleman B, Iverson L, Menendez VP, (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830.
3. Peterson BA, Frizzera G, (1993) Multicentric Castleman's disease. Semin Oncol 20: 636-647.
4. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, et al. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. Journal of Clinical Oncology 28: 3701-3708.
5. Kishimoto T, (2010) IL-6: from its discovery to clinical applications. International Immunology 22: 347-352.
6. May LT, Santhanam U, Sehgal PB, (1991) On the multimeric nature of natural human interleukin-6. Journal of Biological Chemistry 266: 9950-9955.
7. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, et al. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis & Rheumatism 48: 1521-1529.
8. Bataille R, Jourdan M, Zhang XG, Klein B, (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation 84: 2008-2011.
9. Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, et al. (2009) Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clinical Cancer Research 15: 5234-5239.
10. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, et al. (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer 103: 642-646.
11. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation 102: 1369-1376.
12. Guerreiro CS, Ferreira P, Tavares L, Santos PM, Neves M, et al. (2009) Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease. American Journal of Gastroenterology 104: 2241-2249.
13. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD, (2007) IL6 genotypes and colon and rectal cancer. Cancer Causes & Control 18: 1095-1105.
14. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, et al. (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiology, Biomarkers & Prevention 15: 2285-2291.
15. Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, et al. (2006) Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45: 1485-1489.
16. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, et al. (2005) IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunology Letters 96: 241-246.
17. Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, et al. (2012) An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 119: 503-512.
18. Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, et al. (2004) Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes & Immunity 5: 513-516.
19. Mullberg J, Oberthur W, Lottspeich F, Mehl E, Dittrich E, et al. (1994) The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. Journal of Immunology 152: 4958-4968.
20. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM, (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB Journal 15: 43-58.
21. Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, et al. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. American Journal of Human Genetics 80: 716-726.
22. Rafiq S, Frayling TM, Murray A, Hurst A, Stevens K, et al. (2007) A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes & Immunity 8: 552-559.
23. Scheller J, Rose-John S, (2006) Interleukin-6 and its receptor: from bench to bedside. Medical Microbiology & Immunology 195: 173-183.
24. Sehgal PB, (1996) Interleukin-6-type cytokines in vivo: regulated bioavailability. Proceedings of the Society for Experimental Biology & Medicine 213: 238-247.
25. Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM, (1995) Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. Journal of Immunological Methods 186: 171-179.
26. Krakauer T, (1998) Variability in the sensitivity of nine enzyme-linked immunosorbant assays (ELISAs) in the measurement of human interleukin 6. J Immunol Methods 219: 161-167.
27. Schaid DJ, Jacobsen SJ, (1999) Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. American Journal of Epidemiology 149: 706-711.